SG11202112735QA - Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes - Google Patents

Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes

Info

Publication number
SG11202112735QA
SG11202112735QA SG11202112735QA SG11202112735QA SG11202112735QA SG 11202112735Q A SG11202112735Q A SG 11202112735QA SG 11202112735Q A SG11202112735Q A SG 11202112735QA SG 11202112735Q A SG11202112735Q A SG 11202112735QA SG 11202112735Q A SG11202112735Q A SG 11202112735QA
Authority
SG
Singapore
Prior art keywords
povidone
iodine
infection
prevention
topical application
Prior art date
Application number
SG11202112735QA
Inventor
Peter Molloy
Stephen Goodall
Original Assignee
Firebrick Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902006A external-priority patent/AU2019902006A0/en
Application filed by Firebrick Pharma Ltd filed Critical Firebrick Pharma Ltd
Publication of SG11202112735QA publication Critical patent/SG11202112735QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/18Iodine; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79Polymers of vinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11202112735QA 2019-06-10 2020-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes SG11202112735QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902006A AU2019902006A0 (en) 2019-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2020900489A AU2020900489A0 (en) 2020-02-20 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
PCT/AU2020/050586 WO2020232515A1 (en) 2019-06-10 2020-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes

Publications (1)

Publication Number Publication Date
SG11202112735QA true SG11202112735QA (en) 2021-12-30

Family

ID=73459166

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202112735QA SG11202112735QA (en) 2019-06-10 2020-06-10 Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes

Country Status (14)

Country Link
US (3) US11246887B2 (en)
EP (1) EP3980031A4 (en)
JP (1) JP2022538711A (en)
KR (1) KR20220018570A (en)
CN (1) CN114258303A (en)
AU (1) AU2020280226A1 (en)
BR (1) BR112021024916A2 (en)
CA (1) CA3141483A1 (en)
CL (1) CL2021003208A1 (en)
IL (1) IL288742A (en)
MX (1) MX2021015110A (en)
SG (1) SG11202112735QA (en)
WO (1) WO2020232515A1 (en)
ZA (1) ZA202109360B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220018570A (en) 2019-06-10 2022-02-15 화이어브릭 파마 리미티드 Prevention of infection caused by highly pathogenic viruses by topical application of povidone-iodine to the mucous membranes
NL2025641B1 (en) * 2020-04-17 2023-06-22 Veloce Biopharma Llc Methods and compositions for improved treatment of sinus disease
CA3180198A1 (en) * 2020-06-10 2021-12-16 Peter Molloy Improved virucidal formulations
CA3204015A1 (en) * 2020-12-31 2022-07-07 Ntby Moss Llc Formulations of a prophylactic nasal spray and methods of use and manufacture thereof
EP4285920A1 (en) * 2021-02-01 2023-12-06 Dermopartners, S.L. Composition for use as an antiviral in the form of nasal drops and in nebulisers
WO2022235966A1 (en) * 2021-05-05 2022-11-10 Cedars-Sinai Medical Center Uv a light exposure increases mitochondrial anti-viral protein expression in tracheal cells via cell-to-cell communication and uses thereof
FR3122572A1 (en) * 2021-05-07 2022-11-11 Nadine GRISLAIN Bioadhesive pharmaceutical composition comprising PVPI
AU2021203846B2 (en) * 2021-06-10 2022-11-24 Firebrick Pharma Limited Virucidal formulations containing povidone-iodine
CO2021016391A1 (en) * 2021-11-30 2023-06-09 Quifarmedical Company S A S Antiviral liquid pharmaceutical composition against sars-cov-2

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4523589A (en) 1983-06-29 1985-06-18 Krauser Robert S Method and apparatus for treating ailments
JPH04173726A (en) 1990-11-05 1992-06-22 Nippon Zetotsuku Kk Dentifrice composition
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
JPH09151127A (en) 1995-09-29 1997-06-10 Taisho Pharmaceut Co Ltd Composition for pharyngopathy
JP2000169378A (en) 1998-12-10 2000-06-20 Taisho Pharmaceut Co Ltd Composition for pharyngopathy
US20060122082A1 (en) 2000-02-17 2006-06-08 Leonard Paul Foam/spray producing compositions and dispensing system therefor
US6696041B2 (en) * 2002-03-20 2004-02-24 Richard L. Hansen Treatment of colds, flu like infections and other general nasal based infections with a solution containing iodine and other broad spectrum microbicides and a method for its use
AU2003263162B2 (en) * 2002-10-24 2009-05-07 Immupharm A/S Pharmaceutical compositions comprising flavonoids and menthol
JP2004352642A (en) * 2003-05-29 2004-12-16 Meiji Seika Kaisha Ltd Prophylactic against viral infectious disease
CN1203864C (en) 2003-07-23 2005-06-01 南京大学 Spray formulation of providone iodine
WO2006062845A2 (en) 2004-12-09 2006-06-15 The Dial Corporation Compositions having a high antiviral and antibacterial efficacy
WO2012177251A1 (en) 2011-06-22 2012-12-27 Adeda Therapeutics Company Limited Pharmaceutical compositions comprising iodine and steroid and uses thereof for sinus diseases
CN103751274B (en) * 2014-02-20 2016-08-17 河北旺达饲料兽药开发有限公司 A kind of pharmaceutical composition treating duck, goose flaviviridae infections and preparation method thereof
CN106794198A (en) * 2014-07-23 2017-05-31 法尔布里克制药股份有限公司 Use the treatment and prevention of the common cold of PVP-I
KR20170033925A (en) * 2015-09-17 2017-03-28 송경진 Spray compositions having antiviral efficacy and antibacterial agent
KR101935250B1 (en) * 2017-07-04 2019-01-04 김대황 Antiviral and antibacterial composition comprising iodide and osmotic tastant for eye, oral cavity, nasal cavity or inhalation
KR20220018570A (en) 2019-06-10 2022-02-15 화이어브릭 파마 리미티드 Prevention of infection caused by highly pathogenic viruses by topical application of povidone-iodine to the mucous membranes

Also Published As

Publication number Publication date
CN114258303A (en) 2022-03-29
ZA202109360B (en) 2023-10-25
US11969441B2 (en) 2024-04-30
AU2020280226A1 (en) 2022-01-06
WO2020232515A1 (en) 2020-11-26
EP3980031A1 (en) 2022-04-13
BR112021024916A2 (en) 2022-02-15
CL2021003208A1 (en) 2022-09-30
US11246887B2 (en) 2022-02-15
US20220168338A1 (en) 2022-06-02
CA3141483A1 (en) 2020-11-26
MX2021015110A (en) 2022-02-22
EP3980031A4 (en) 2022-08-17
IL288742A (en) 2022-02-01
JP2022538711A (en) 2022-09-06
US20220088067A1 (en) 2022-03-24
US20200384016A1 (en) 2020-12-10
KR20220018570A (en) 2022-02-15

Similar Documents

Publication Publication Date Title
IL288742A (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
EP3996716A4 (en) Compounds useful to treat influenza virus infections
EP4265299A3 (en) Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
PH12017500207B1 (en) Indoles for use in influenza virus infection
EA201790571A1 (en) PYRROPHYRIMIDINES FOR APPLICATION IN INFECTION CAUSED BY THE FLU VIRUS
MY197408A (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
EA201891278A1 (en) HETEROCYCLIC INDOLS TO BE USED FOR INFECTION CAUSED BY THE FLU VIRUS
CA3010327A1 (en) Aryl substituted pyrimidines for use in influenza virus infection
EP3423075A4 (en) Stapled intracellular-targeting antimicrobial peptides to treat infection
WO2016142445A3 (en) Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
WO2015024010A3 (en) Substituted hydroxamic acid compounds
EP3846616A4 (en) Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
SI3400225T1 (en) Pentanoic acids substituted by pyrrolo-(2-3,b)pyrimidine-pyridines for the treatment of influenza viral infections
ZA202002093B (en) Antibacterial compounds
MX2017009094A (en) Polymyxin derivative and uses thereof.
EA201890186A1 (en) APPLICATION OF MICROBACTERIA STRAINS FOR OBTAINING ANTIBACTERIAL AGENTS
WO2018109042A3 (en) Antimicrobial peptides
MX2019011908A (en) Anti-bacterial peptide macrocycles and use thereof.
AU2019902006A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2018902045A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2018901988A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2017902102A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2020900489A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
AU2016902095A0 (en) Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes
EP3551191A4 (en) Aminoglycoside potentiation for treatment of pulmonary bacterial infection